Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.

Gilbert PB, Huang Y, Juraska M, Moodie Z, Fong Y, Luedtke A, Zhuang Y, Shao J, Carpp LN, Jackson N, Chambonneau L, Bouckenooghe A, Zambrano B, Frago C, Pallardy S, Noriega F.

Am J Trop Med Hyg. 2019 May 20. doi: 10.4269/ajtmh.18-0534. [Epub ahead of print]

PMID:
31115304
2.

Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease.

Pasin C, Halloran ME, Gilbert PB, Langevin E, Ochiai RL, Pitisuttithum P, Capeding MR, Carrasquilla G, Frago C, Cortés M, Chambonneau L, Moodie Z.

PLoS One. 2018 Dec 13;13(12):e0207878. doi: 10.1371/journal.pone.0207878. eCollection 2018.

3.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team.

Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.

4.

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.

Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, Moodie Z, Westling T, Mascareñas C, Frago C, Cortés M, Chansinghakul D, Noriega F, Bouckenooghe A, Chen J, Ng SP, Gilbert PB, Gurunathan S, DiazGranados CA.

N Engl J Med. 2018 Jul 26;379(4):327-340. doi: 10.1056/NEJMoa1800820. Epub 2018 Jun 13.

5.

Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.

Moodie Z, Juraska M, Huang Y, Zhuang Y, Fong Y, Carpp LN, Self SG, Chambonneau L, Small R, Jackson N, Noriega F, Gilbert PB.

J Infect Dis. 2018 Feb 14;217(5):742-753. doi: 10.1093/infdis/jix609.

6.

Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.

Lhomme E, Richert L, Moodie Z, Pasin C, Kalams SA, Morgan C, Self S, De Rosa SC, Thiébaut R.

PLoS One. 2016 Apr 28;11(4):e0152952. doi: 10.1371/journal.pone.0152952. eCollection 2016.

7.

Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials.

Fiore-Gartland A, Manso BA, Friedrich DP, Gabriel EE, Finak G, Moodie Z, Hertz T, De Rosa SC, Frahm N, Gilbert PB, McElrath MJ.

PLoS One. 2016 Feb 10;11(2):e0147812. doi: 10.1371/journal.pone.0147812. eCollection 2016.

8.

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083 Study Group and the NIAID HVTN.

J Infect Dis. 2016 Feb 15;213(4):541-50. doi: 10.1093/infdis/jiv496. Epub 2015 Oct 15.

9.

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.

Moodie Z, Metch B, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, Bentley C, Gilbert PB, Robertson M, Kublin J, Corey L, Gray GE.

PLoS One. 2015 Sep 14;10(9):e0137666. doi: 10.1371/journal.pone.0137666. eCollection 2015.

10.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.

Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB.

PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.

11.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study.

Huang Y, Duerr A, Frahm N, Zhang L, Moodie Z, De Rosa S, McElrath MJ, Gilbert PB.

PLoS One. 2014 Nov 4;9(11):e108631. doi: 10.1371/journal.pone.0108631. eCollection 2014.

12.

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath MJ, Robertson M, Kublin J, Corey L; HVTN 503/Phambili study team.

Lancet Infect Dis. 2014 May;14(5):388-96. doi: 10.1016/S1473-3099(14)70020-9. Epub 2014 Feb 20.

13.

Optimizing viable leukocyte sampling from the female genital tract for clinical trials: an international multi-site study.

McKinnon LR, Hughes SM, De Rosa SC, Martinson JA, Plants J, Brady KE, Gumbi PP, Adams DJ, Vojtech L, Galloway CG, Fialkow M, Lentz G, Gao D, Shu Z, Nyanga B, Izulla P, Kimani J, Kimwaki S, Bere A, Moodie Z, Landay AL, Passmore JA, Kaul R, Novak RM, McElrath MJ, Hladik F.

PLoS One. 2014 Jan 15;9(1):e85675. doi: 10.1371/journal.pone.0085675. eCollection 2014.

14.

New clinical trial designs for HIV vaccine evaluation.

Moodie Z, Janes H, Huang Y.

Curr Opin HIV AIDS. 2013 Sep;8(5):437-42. doi: 10.1097/COH.0b013e328363d46a. Review.

15.

Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners.

Pala P, Serwanga J, Watera C, Ritchie AJ, Moodie Z, Wang M, Goonetilleke N, Birabwa E, Hughes P, Senkaali D, Nakiboneka R, Grosskurth H, Haynes B, McMichael A, Kaleebu P; Center for HIV/AIDS Vaccine Immunology.

J Virol. 2013 Aug;87(16):9053-63. doi: 10.1128/JVI.00721-13. Epub 2013 Jun 12.

16.

Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?

Gray GE, Metch B, Churchyard G, Mlisana K, Nchabeleng M, Allen M, Moodie Z, Kublin J, Bekker LG; HVTN 503 team.

Vaccine. 2013 Apr 12;31(16):2089-96. doi: 10.1016/j.vaccine.2013.01.031. Epub 2013 Jan 29.

17.

Comparing and combining data across multiple sources via integration of paired-sample data to correct for measurement error.

Huang Y, Huang Y, Moodie Z, Li S, Self S.

Stat Med. 2012 Dec 10;31(28):3748-59. doi: 10.1002/sim.5446. Epub 2012 Jul 5.

18.

Comparison of sexual behavior and HIV risk between two HIV-1 serodiscordant couple cohorts: the CHAVI 002 study.

Ritchie AJ, Kuldanek K, Moodie Z, Wang ZM, Fox J, Nsubuga RN, Legg K, Birabwa EF, Kaleebu P, McMichael AJ, Watera C, Goonetilleke N, Fidler S.

PLoS One. 2012;7(5):e37727. doi: 10.1371/journal.pone.0037727. Epub 2012 May 22.

19.

Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories.

Moodie Z, Price L, Janetzki S, Britten CM.

Methods Mol Biol. 2012;792:185-96. doi: 10.1007/978-1-61779-325-7_15.

PMID:
21956511
20.

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network.

PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225. Epub 2011 Aug 3.

21.

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG; HVTN 503/Phambili study team.

Lancet Infect Dis. 2011 Jul;11(7):507-15. doi: 10.1016/S1473-3099(11)70098-6. Epub 2011 May 11. Erratum in: Lancet Infect Dis. 2011 Jul;11(7):495.

22.

Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals.

Ritchie AJ, Campion SL, Kopycinski J, Moodie Z, Wang ZM, Pandya K, Moore S, Liu MK, Brackenridge S, Kuldanek K, Legg K, Cohen MS, Delwart EL, Haynes BF, Fidler S, McMichael AJ, Goonetilleke N.

J Virol. 2011 Apr;85(7):3507-16. doi: 10.1128/JVI.02444-10. Epub 2011 Jan 26.

23.

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).

Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, De Rosa SC, McElrath MJ; NIAID HIV Vaccine Trials Network.

PLoS One. 2010 Oct 27;5(10):e13579. doi: 10.1371/journal.pone.0013579.

24.

Response definition criteria for ELISPOT assays revisited.

Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM.

Cancer Immunol Immunother. 2010 Oct;59(10):1489-501. doi: 10.1007/s00262-010-0875-4. Epub 2010 Jun 15.

25.

Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype.

Dinges WL, Richardt J, Friedrich D, Jalbert E, Liu Y, Stevens CE, Maenza J, Collier AC, Geraghty DE, Smith J, Moodie Z, Mullins JI, McElrath MJ, Horton H.

J Virol. 2010 May;84(9):4461-8. doi: 10.1128/JVI.02438-09. Epub 2010 Feb 10.

26.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1894-1905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov 13.

27.

Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination.

Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, Chiu YL, McElrath MJ, De Rosa SC.

J Immunol Methods. 2007 May 31;323(1):39-54. Epub 2007 Apr 3.

28.

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS; VRC 201/203 Study Team.

Vaccine. 2007 Feb 9;25(8):1513-25. Epub 2006 Nov 7.

29.

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.

Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR, Nabel GJ; Vaccine Research Center 004 Study Team.

J Infect Dis. 2006 Dec 15;194(12):1650-60. Epub 2006 Nov 8.

30.

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.

Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, Butman BT, Gall JG, King CR, Andrews CA, Sheets R, Gomez PL, Mascola JR, Nabel GJ, Graham BS; Vaccine Research Center 006 Study Team.

J Infect Dis. 2006 Dec 15;194(12):1638-49. Epub 2006 Nov 8. Erratum in: J Infect Dis. 2009 Oct 15;200(8):1352-3.

31.

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

Follmann D, Duerr A, Tabet S, Gilbert P, Moodie Z, Fast P, Cardinali M, Self S.

J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):49-60.

32.

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.

Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS.

Clin Vaccine Immunol. 2006 Nov;13(11):1267-77. Epub 2006 Sep 20.

33.

Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.

Moodie Z, Huang Y, Gu L, Hural J, Self SG.

J Immunol Methods. 2006 Aug 31;315(1-2):121-32. Epub 2006 Aug 15.

PMID:
16959262
34.

Statistical evaluation of HIV vaccines in early clinical trials.

Moodie Z, Rossini AJ, Hudgens MG, Gilbert PB, Self SG, Russell ND.

Contemp Clin Trials. 2006 Apr;27(2):147-60. Epub 2006 Jan 19.

PMID:
16426900
35.

Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.

Kong WP, Huang Y, Yang ZY, Chakrabarti BK, Moodie Z, Nabel GJ.

J Virol. 2003 Dec;77(23):12764-72.

36.

Overcoming immunity to a viral vaccine by DNA priming before vector boosting.

Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ.

J Virol. 2003 Jan;77(1):799-803.

Supplemental Content

Loading ...
Support Center